Digestive Diseases and Sciences

, Volume 53, Issue 5, pp 1417–1421

CYP1B1 Polymorphisms and K-ras Mutations in Patients with Pancreatic Ductal Adenocarcinoma

  • Marta Crous-Bou
  • Immaculata De Vivo
  • Miquel Porta
  • José A. Pumarega
  • Tomàs López
  • Joan Alguacil
  • Eva Morales
  • Núria Malats
  • Juli Rifà
  • David J. Hunter
  • Francisco X. Real
  • For the PANKRAS II Study Group
Original Paper

DOI: 10.1007/s10620-008-0235-9

Cite this article as:
Crous-Bou, M., De Vivo, I., Porta, M. et al. Dig Dis Sci (2008) 53: 1417. doi:10.1007/s10620-008-0235-9

Abstract

The frequency of CYP1B1 polymorphisms in pancreatic cancer has never been reported. There is also no evidence on the relationship between CYP1B1 variants and mutations in ras genes (K-, H- or N-ras) in any human neoplasm. We analyzed the following CYP1B1 polymorphisms in 129 incident cases of pancreatic ductal adenocarcinoma (PDA): the m1 allele (Val to Leu at codon 432) and the m2 allele (Asn to Ser at codon 453). The calculated frequencies for the m1 Val and m2 Asn alleles were 0.45 and 0.68, respectively. CYP1B1 genotypes were out of Hardy–Weinberg equilibrium; this was largely due to K-ras mutated PDA cases. The Val/Val genotype was over five times more frequent in PDA cases with a K-ras mutation than in wild-type cases (OR = 5.25; P = 0.121). In PDA, polymorphisms in CYP1B1 might be related with K-ras activation pathways.

Keywords

Pancreatic neoplasmsCYP1B1 polymorphismsK-ras oncogeneras genes

Abbreviations

PANKRAS

Multicenter prospective study on the role of the K-ras and other genetic alterations in the diagnosis, prognosis, and etiology of pancreatic and biliary diseases

PDA

Pancreatic ductal adenocarcinoma

CYP1B1

Cytochrome P450 1B1

PAHs

Polycyclic aromatic hydrocarbons

OR

Odds ratio

CI

Confidence interval

Copyright information

© Springer Science+Business Media, LLC 2008

Authors and Affiliations

  • Marta Crous-Bou
    • 1
    • 2
  • Immaculata De Vivo
    • 3
    • 4
  • Miquel Porta
    • 1
    • 2
  • José A. Pumarega
    • 1
  • Tomàs López
    • 1
  • Joan Alguacil
    • 1
    • 5
  • Eva Morales
    • 1
  • Núria Malats
    • 1
  • Juli Rifà
    • 6
  • David J. Hunter
    • 3
    • 4
  • Francisco X. Real
    • 1
    • 7
  • For the PANKRAS II Study Group
  1. 1.Institut Municipal d’Investigació Mèdica (IMIM)CIBER de Epidemiología y Salud Pública (CIBERESP)BarcelonaSpain
  2. 2.School of MedicineUniversitat Autònoma de BarcelonaBarcelonaSpain
  3. 3.Harvard School of Public HealthBostonUSA
  4. 4.Channing LaboratoryBrigham and Women’s HospitalBostonUSA
  5. 5.Department of Environmental Biology & Public HealthUniversidad de HuelvaHuelvaSpain
  6. 6.Hospital Son DuretaPalma de MallorcaSpain
  7. 7.Universitat Pompeu FabraBarcelonaSpain